Onvansertib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.

**Synonyms:** - NMS-1286937 - ONVANSERTIB - PCM 075 - PCM-075 - PLK-1 Inhibitor PCM-075 - PLK1 Inhibitor PCM-075 - Polo-like Kinase 1 Inhibitor NMS-1286937 - Polo-like Kinase 1 Inhibitor PCM-075